tbuckley/cabot-search huggingface dataset:
CIRCULATORY REACTIONS TO HEMORRHAGE
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
Journal: Journal of Clinical Oncology (1996)

PURPOSE The primary objective was to determine clinical practice guidelines for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast and colorectal cancers. These guidelines are intended for use in the care of patients outside of clinical trials. METHODS Six tumor markers for colorectal cancer and seven for breast cancer were considered. They could be recommended or not for routine use or for special circumstances. In general, the significant health outcomes identified for use in making clinical practice guidelines (overall survival, disease-free survival, quality of life, lesser toxicity, and cost-effectiveness) were used when data were available. Expert consensus was used to inform the recommendations for use of tumor markers when published evidence was insufficient. A computerized literature search was performed using Medline. In addition to reports collected by individual panel members, all articles published in the English-speaking literature from January 1989 to April 1994 were collected for review and distributed to all members of the Panel. Values for use, utility, and levels of evidence were assigned by the expert reviewers and approved by the Panel. Tumor markers were assigned benefit if they had prognostic or predictive value that would lead to the favorable outcomes listed above. Harms considered were inappropriate disease management, and excess cost without definable benefit. Costs were considered but were never the sole determinant of a recommendation. RESULTS AND CONCLUSION For colorectal cancer, it is recommended that carcinoembryonic antigen (CEA) levels be measured preoperatively if it would change surgical management. It is recommended that CEA levels be monitored every 2 to 3 months for &gt; or = 2 years, if resection of liver metastasis would be clinically indicated. The data are insufficient to recommend the routine use of lipid-associated sialic acid (LASA), CA 19-9, DNA index, DNA flow cytometric proliferation analysis, p53 tumor suppressor gene, and ras oncogene. For breast cancer, estrogen receptor and progesterone receptor are recommended to be measured on every primary specimen, but on subsequent specimens only if it would lead to a change in management. The data are insufficient to recommend the routine use of DNA index, DNA flow cytometric proliferation analysis, CA 15-3, CEA, c-erbB-2, p53 or cathepsin-D. In the absence of readily measurable disease, CA 15-3 and CEA levels can be used to document treatment failure. New markers and new evidence will be evaluated by annual update of these guidelines.
Factor VIII concentrates
Authors: O. D. Ratnoff
Journal: JAMA (1986)

<h3>To the Editor.—</h3> I am no connoisseur of Cubism, but know something of musical instruments, and in consequence I feel a need to question Dr Mark S. Litwin's<sup>1</sup>comments on the July 26, 1985, cover illustration of George Braque's<i>Aria de Bach</i>. Can a painting of a violin that is actually the painting of a guitar still be a painting of a violin?
Chenotherapy for gallstone dissolution. I. Efficacy and safety
Authors: J. L. Thistle
Journal: JAMA (1978)

Clinical experience with chenodeoxycholic acid therapy for dissolving gallstones is reported, with particular attention to determinants of response. Of 12 patients receiving 15 mg/kg/day or more, ten responded (83%); only 15 of 40 patients (38%) receiving less than 15 mg/kg/day responded. Large solitary stones and stones in gallbladders that visualized poorly after oral cholecystography had a lower response rate. Radiopaque stones did not respond in 18 patients. Five of ten patients with stones in the common bile duct responded. Small, dose-related elevations in SGOT were the only biochemical abnormality observed. Liver biopsy specimens showed no notable abnormality. Diarrhea was an infrequent problem. Stones recurred in three of 15 patients during six to 48 months of observation without treatment. Chenodeoxycholic acid, when given in adequate dosage, continues to appear promising as medical therapy for asymptomatic radiolucent gallstones in radiologically visualizing gallbladders. (<i>JAMA</i>239:1041-1046, 1978)
Doctor's orders
Authors: Robert Gaudet
Journal: JAMA (1986)

<h3>To the Editors.—</h3> The article by Hoeg et al<sup>1</sup>provided valuable guidelines for the evaluation and treatment of persons with elevated levels of serum lipids. Individuals with serum cholesterol in the upper tenth percentile for their age and sex are considered to be at high risk for atherosclerotic sequelae. Those with levels in the 75th to 90th percentiles are considered to be at moderate risk. The authors advocate screening virtually all persons for elevated cholesterol levels using automated analyzers. These devices output the results of chemical panels or single cholesterol values on preprinted forms. In many laboratories the results are compared with a previously determined normal range. Chemistry values above the normal range are flagged (usually with "H," "+," or "*") or set aside in separate columns to indicate abnormality. Normal ranges are set according to manufacturers' specifications based on population studies or from the laboratory's previous experience. Although techniques used
Propranolol Withdrawal
Authors: STAN NATTEL
Journal: Annals of Internal Medicine (1978)

Letters and Corrections1 August 1978Propranolol WithdrawalSTAN NATTEL, M.D., JOHN SHANKS, M.D., ROBERT E. RANGNO, M.D.STAN NATTEL, M.D., JOHN SHANKS, M.D., ROBERT E. RANGNO, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-89-2-288_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Boudoulas and colleagues (1) have reported transient hypersensitivity to beta agonists after abrupt propranolol withdrawal. There is possible danger in extrapolating the time course of the phenomena noted after 48 h of propranolol administration to that which might occur after long-term propranolol therapy. Evidence has been presented to show that beta adrenergic hypersensitivity peaks at 5 to 7 days and continues up to 14 days after abrupt discontinuation of chronic propranolol therapy (2).This time course has important implications with respect to the safe withdrawal of propranolol. The onset and duration of hypersensitivity in the latter study...References1. BOUDOULAS H, LEWIS R, KATES R, and DALAMANGAS G Hypersensitivity to adrenergic stimulation after propranolol withdrawal in normal subjects. Ann Intern Med 87:433-436, 1977 LinkGoogle Scholar2. NATTEL S, RANGNO R, and VAN LOON G: Mechanism of propranolol withdrawal phenomena (abstract). Clin Res 26:292A, 1978 Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: STAN NATTEL, M.D.; JOHN SHANKS, M.D.; ROBERT E. RANGNO, M.D.Affiliations: Montreal General and Royal Victoria Hospitals Montreal, PQ H3G IA4 Canada PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAbrupt withdrawal of atenolol in patients with severe angina. Comparison with the effects of treatment.Comparison of withdrawal phenomena after propranolol, metoprolol, and pindololComparison of withdrawal phenomena after propranolol, metoprolol and pindolol.Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol scheduleComparison of Withdrawal Phenomena After Propranolol, Metoprolol and PindololMechanism of propranolol withdrawal phenomena. 1 August 1978Volume 89, Issue 2Page: 288-288KeywordsHypersensitivity ePublished: 1 December 2008 Issue Published: 1 August 1978 PDF downloadLoading ...
将hCONSORT标准用作常见皮肤病的草药干预的报告标准:一项系统回顾
Authors: J. Ornelas, E. Routt, P. Kallis, H. Lev-Tov
Journal: British Journal of Dermatology (2018)

Summary 西方国家越来越多地将补充和替代医疗(CAM)用于各种症状,包括皮肤相关症状。替代医疗是一种在西药范围之外的治疗方法,而补充医疗则将此类治疗与西药相结合。尽管CAM的使用范围越来越广,但由于缺少支持的可靠科学研究,因此西方的保健服务提供者尚未将其结合到实践中。有一种方法可以消除广泛的公共使用与缺少可靠数据之间的差距,那就是改进研究在医学期刊上的报告方式。2006年,业界发布了一些指南,旨在帮助科学研究人员对中医药的使用开展质量研究。这些指南被称为有关报告草药干预的CONSORT扩展标准(hCONSORT),于2006年发布。我们希望调查这些指南在皮肤医学中的应用情况。作为我们在美国开展的研究的一部分,我们查看了对将植物药物用于治疗三种常见皮肤症状进行调查的科学研究:痤疮、异位性湿疹和银屑病。我们专注于在2009年至2014年之间发布的文章,并将其对hCONSORT指南的遵守程度进行评级。出乎意料的是,我们发现大部分科学研究只遵守了不到50%的hCONSORT指南。基于这些发现,我们建议科学家在开展有关使用中医药的研究时应遵守这些指南,并且科学期刊的编辑在介绍评估中医药使用的文章时应鼓励遵守这些指南。这样将有助于西方保健服务从业者安全有效地将CAM结合到传统医学中。
The Chlamydia epidemic
Authors: K. K. Holmes
Journal: JAMA (1981)

<h3>JAMA:</h3> What are the most important facts that practitioners should know about diseases caused by<i>Chlamydia trachomatis</i>? <h3>Holmes:</h3> I believe that there are five crucial facts concerning chlamydial infections that practitioners should know. Chlamydial infections are epidemic in this country, yet they are neither well recognized nor correctly treated in many instances. Nationally, we are observing alarming increases in the number of cases of ectopic pregnancy and salpingitis, a large proportion of which may result from chlamydial infection. Since each of these ectopic pregnancies represents one fetal death, this constitutes an epidemic of fetal deaths. Chlamydial infections during pregnancy should receive much greater attention. These infections may lead to postpartum endometritis in the mother and may be transmitted to the infant, causing pneumonia or eye infection. Our group has disturbing data showing that the fetuses of women who have chlamydial infections during pregnancy are at increased risk
Strahlentherapie, Munich
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000
Authors: A. E. Washington
Journal: JAMA (1991)

Pelvic inflammatory disease (PID) and its sequelae affect millions of women in the United States at substantial costs. To estimate these total costs annually and to determine payment sources, we analyzed data from local, state, and national sources. Direct costs for PID and PID-associated ectopic pregnancy and infertility were estimated to be $2.7 billion, and indirect costs were estimated to be $1.5 billion, for a total cost of $4.2 billion in 1990. Overall, private insurance covered the largest portion of the direct costs of PID (41%), followed by public payment sources (30%). However, the proportion of payments made by private insurance appears to be decreasing, while that by public payment sources is increasing. In the year 2000, costs associated with PID are projected to approach $10 billion if the current PID incidence persists, with an increasing proportion of this expense burdening public institutions. Prevention of PID is needed both to reduce human suffering and to contain rising costs. (<i>JAMA</i>. 1991;266:2565-2569)
Prolactin-Secreting Pituitary Adenomas
Authors: William R. Keye
Journal: JAMA (1980)

Hypocycloidal tomograms of the sella turcica and serum prolactin concentrations were obtained in 146 women with amenorrhea, galactorrhea, or both to diagnose prolactin-secreting pituitary adenomas. Findings suggesting an adenoma, ie, abnormal tomogram and elevated serum prolactin concentration, were found in 24.6% (16/65) of previously unscreened patients and 59.2% (48/81) of prescreened patients. The combination of an abnormal tomogram and elevated prolactin level was relatively specific for an adenoma, as 91% (42/46) of women with these findings who underwent surgery had histologically confirmed tumors. Tumors occurred in women from 15 to 45 years of age, with amenorrhea or galactorrhea ranging from less than six months to more than 20 years in duration. Some women in this series also had obesity, rapid weight loss, polycystic ovarian syndrome, amenorrhea following discontinuance of oral contraceptive use, or emotional stress. (<i>JAMA</i>244:1329-1332, 1980)
Phase I study of cabazitaxel-PF induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Authors: Adnan Khan, Rita Babu, Amiya Vaz, Michele Deyne-Borza, Alicia Price, Richard Lorne Bakst, Vishal Gupta, Brett Miles, Marshall R. Posner, Krzysztof Misiukiewicz
Journal: Journal of Clinical Oncology (2015)

e17082 Background: Docetaxel has been used in induction chemotherapy (IC) in combination with Cisplatin and 5-FU in patients with squamous cell carcinoma of the head and neck (SCCHN). A new generation of taxanes, such as cabazitaxel, is emerging and may possess stronger antitumor activity and/or decreased normal tissue toxicity. In the dose escalation design of this study, the primary endpoint of the study had been reached; the determined MTD for cabazitaxel was 22.5mg/m2 given in combination with cisplatin at 75 mg/m2 and 5-FU at 3200 mg/m2(PF). Methods: The analyzed study sample consisted of 3 patients from the dose-escalation phase of the study and 10 from the expansion cohort. The study enrolled HPV+ heavy smokers, defined as having > 20 pack year history, and HPV- patients. Thirteen patients were enrolled: 12 males, 1 female. Eleven out of 13 patients (85%) were enrolled with an ECOG performance status (PS) of 0. Two out of 13 patients (15%) were enrolled with a PS of 1. Ten out of 13 patients completed IC with Cabazitaxel-PF. Two patients are currently receiving treatment and one patient could not complete IC due to a not-treatment related death due to a line infection and sepsis with no neutropenia. Human Papilloma Virus (HPV) status was determined by immunohistochemistry (IHC) for p16 and HPV16 by PCR. With a total of 13 patients, 5 were HPV+, 7 were HPV- , and 1 was not evaluated. The secondary objective of the study was to assess Best Overall Response Rate based on clinical and radiographic responses, progression free survival (PFS) and overall survival (OS). Results: Complete responses (CR) were observed in 3/10 patients (30%), partial responses (PR) in 6/10 (60%), and 1/10 (10%) had progressive disease (PD) (Table 1). CR was seen in 1/4 (25%) HPV+ patients and in 2/6 (33%) HPV- patients. PR was seen in 3/4 HPV+ (75%) and 3/6 (50%) HPV- patients. PD was seen in 1 HPV- patient. No unexpected events related to Cabazitaxel-PF were observed in this cohort of patients. Conclusions: Cabazitaxel-PF IC at recommended dose of 22.5mg/m2was generally well tolerated and showed signs of activity in patients with SCCHN. Clinical trial information: NCT01379339. Responses HPV + HPV - Total CR 1 2 3/10 (30%) PR 3 3 6/10 (60%) PD 0 1 1/10 (10%)
American Journal of Psychiatry, Hanover, NH
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TREATMENT OF FRACTURE OF MALAR BONE WITH DISLOCATION INTO MAXILLARY SINUS
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEWS
Journal: Circulation (1965)

This volume contains more than 50 reports of individual investigations on a variety of studies relative to the effects of anticoagulant therapy on coronary artery disease.Many of the presenta- tions contain statistical data on the efficacy of therapy, some of them not previously published.The viewpoints of the committed, the uncom- mitted, and the nonaligned are all represented and the discussions are exceedingly frank.The use of coumarin and heparin therapy in short- and long-term therapeutic programs is presented in considerable detail.In addition, there are several papers on pathology and thrombogenesis.Thrombolytic therapy is mentioned only briefly.Many of the papers contain excellent bibliographies.
Correction
Journal: BMJ (1963)

SIR,-! am chairman of a committee which has been set up by the Secretary of State for Scotland with the following terms of reference: " To review the dental staffing structure in Scottish hospitals in the light of the principles set out in the report of the joint working party on the medical staffing structure in the hospital service; and to make recommenda- tions about the organization of the dental staffing in each hospital region on the number, type, and distribution of posts required."The setting up of this committee follows the agreement between the Government and the dental profession to apply the principles of the Platt report of 1961 to hospital dental staffing.The committee is now beginning its deliberations.and I am writing in the hope that you will allow me to use your columns to issue a general invitation to your readers to submit written evidence to the committee on any aspect of hospital dental staffing.All evidence
Orphan airlift. Enteric pathogens isolated from Vietnamese children immigrating to the United States
Authors: R. Goldsmith
Journal: JAMA (1976)

Isolation studies for bacterial and parasitic agents were carried out on stool specimens from Vietnamese infants at the time of their mass airlift to the United States. One or more bacterial pathogens were found in 49% of the 367 stool specimens cultured. The isolates included enteropathogenic<i>Escherichia coli</i>(161),<i>Shigella</i>(16),<i>Salmonella</i>(15), but no<i>Salmonella typhi</i>or<i>Vibrio cholerae</i>. Parasites identified in 88 stool specimens included<i>Giardia lamblia</i>(10),<i>Ascaris lumbricoides</i>(7), and<i>Entamoeba histolytica</i>(1). Transmission of agents to volunteers probably occurred, because 48% of 272 adults questioned had diarrhea shortly after caring for the children, and stool cultures from these adults resulted in the isolation of<i>E coli</i>(105),<i>Salmonella</i>(1), and<i>Shigella</i>(3). (<i>JAMA</i>235:2114-2116, 1976
Antibiotic Produces Remissions
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal